Fidelity Investments’s GT Biopharma GTBP Stock Holding History

Fidelity Investments’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,000	Closed	-$408	–	5637
2026 Q1	$408	Buy	+1,000	New	+$546	﹤0.01%	5183
2024 Q2	–	Sell	-61	Closed	-$271	–	5486
2024 Q1	$271	Buy	+61	New	+$322	﹤0.01%	4896
2023 Q4	–	Sell	-5	Closed	-$36	–	5521
2023 Q3	$36	Sell	5 -763	-99%	-$6.31K	﹤0.01%	4985
2023 Q2	$7.19K	Sell	768 -928	-55%	-$9.62K	﹤0.01%	4254
2023 Q1	$28K	Hold	1,696	–	–	﹤0.01%	3692
2022 Q4	$45.5K	Sell	1,696 -29	-2%	-$1.45K	﹤0.01%	3473
2022 Q3	$91K	Sell	1,725 -116	-6%	-$8.87K	﹤0.01%	3288
2022 Q2	$165K	Buy	1,841 +129	+8%	+$9.78K	﹤0.01%	3173
2022 Q1	$148K	Buy	+1,712	New	+$151K	﹤0.01%	3324
2021 Q4	–	Sell	-4	Closed	-$1K	–	4596
2021 Q3	$1K	Buy	4 +3	+300%	+$903	﹤0.01%	4142
2021 Q2	$0	Buy	+1	New	+$416	﹤0.01%	4505

Other funds holding GTBP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

OWA

Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

4WM

49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return

Alongside Austin, Texas $525M AUM

Fidelity Investments's GTBP Position: Q2 2026 in Review

Fidelity Investments sold out of GT Biopharma (GTBP) in Q2 2026, closing a stake of 1,000 shares — an estimated $408 sold.

Fidelity Investments first reported a position in GTBP in Q2 2021 and held it in 11 quarters. The position peaked at $165K in Q2 2022. 59 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

Fidelity Investments reported no remaining GT Biopharma position as of Q2 2026 after selling out during the quarter.
Fidelity Investments sold 1,000 GT Biopharma shares in Q2 2026, an estimated $408.
Fidelity Investments first reported a position in GT Biopharma in Q2 2021 and held it in 11 quarters.
Fidelity Investments's GT Biopharma position peaked at $165K in Q2 2022.
59 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.